KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$58.37
-1.65% today
Updated 2026-06-05
Market cap
$3.99B
P/E ratio
57.02
P/S ratio
5.29x
EPS (TTM)
$0.91
Dividend yield
—
52W range
$26 – $60
Volume
0.7M
Kiniksa Pharmaceuticals Ltd (KNSA) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed KNSA price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$58.37
Today
Analyst consensus
$60.86
+4.27% · 12M
2030 Base
$58.70
+0.57% future
NPV today
$46.06
@ 5% WACC
9 analysts:
7 Buy2 Hold0 Sell
Management guidance
No explicit CEO revenue targets found in available filings. Company demonstrated 60.09% YoY revenue growth in 2025 ($677.56M) and 37.48% growth guidance for 2026 to $931.53M. Management emphasizes portfolio execution with ARCALYST (rilonacept) expansion in recurrent pericarditis and pipeline advancement (KPL-387 orphan designation for pericarditis). No specific 2030 targets disclosed, suggesting management maintaining flexibility on outer-year guidance.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
KNSA · Kiniksa Pharmaceuticals Ltd · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$-25.39
NPV today: $-25.39
Base case (2030)
$58.70
NPV today: $46.06
Bull case (2030)
$184.84
NPV today: $145.04
WallStSmart.com
KNSA financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.7B | $0.9B | $1.1B | $1.4B | $1.7B | $2.0B |
| Revenue growth | 60.1% | 50.5% | 29.4% | 22.7% | 16.7% | 14.3% |
| Net margin | — | 6.6% | 7.8% | 7.9% | 7.8% | 7.7% |
| EPS | $0.74 | $1.28 | $1.82 | $2.34 | $2.81 | $3.24 |
| Diluted shares | — | 47M | 47M | 47M | 47M | 48M |
| Net debt | — | $107.62M | $657.62M | $1.36B | $2.21B | $3.21B |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $55.65 | $56.39 | $60.35 | $61.11 | $58.70 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $2.0B | $2.0B | $2.0B |
| P/S multiple | 1.0x | 3.0x | 6.0x |
| Diluted shares | 48M | 48M | 48M |
| Net debt | $3.21B | $3.21B | $3.21B |
| Implied P/E † | -8x | 18x | 57x |
| 2030 Price | $-25.39 | $58.70 | $184.84 |
| NPV @ 5% | $-25.39 | $46.06 | $145.04 |
† Implied P/E: Multiples remain elevated across all three scenarios because KNSA is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $58.70 base case
KNSA catalysts and risks
Growth catalysts
+ ARCALYST label expansion in recurrent pericarditis driving revenue acceleration through 2027-2028
+ KPL-387 orphan drug designation progression; potential market exclusivity if approved
+ Portfolio optimization and M&A potential given strong cash position ($459M net cash Q1 2026)
+ International market penetration for existing rare disease franchises
+ Operating leverage improvement as platform matures; 12.36% operating margin expanding toward 15-18%
Key risks
- Pharma competition and market saturation in rare disease inflammatory segments post-2028
- Regulatory risk on label expansions and pipeline candidates (KPL-387, others)
- Insider selling activity (CEO, CMO, CFO systematic exits via Rule 10b5-1 plans April-May 2026) suggests valuation concerns at current price levels ($53.65)
- High P/E (59.1x) and P/S (5.47x) ratios limit margin of safety; valuation reset risk if growth decelerates below 25%
- Scale challenges: at $1B+ revenue, maintaining >30% growth becomes increasingly difficult; TAM constraints in rare inflammatory disease space
Methodology · Kiniksa Pharmaceuticals Ltd 2030 stock forecast model
Kiniksa Pharmaceuticals Ltd 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 9 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (3% cumulative for KNSA by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($3.21B by 2030) |
| 3. Time value | NPV calculated using 5% WACC (CAPM: beta 0.172) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 3.0x / bull 6.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
KNSA price target FAQ
What is the KNSA price target for 2030?
WallStSmart's Kiniksa Pharmaceuticals Ltd 2030 base case is $58.70 per share, with a bull case of $184.84 and bear case of $-25.39. The NPV of the base case discounted to today at 5% WACC is $46.06.
How is the Kiniksa Pharmaceuticals Ltd 2030 stock forecast calculated?
The KNSA 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the KNSA price target account for dilution?
Kiniksa Pharmaceuticals Ltd is projected to grow diluted share count from 46M to 48M by 2030 (a 3% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 3%.
What is the analyst consensus on KNSA stock?
9 analysts cover KNSA with an average 12-month price target of $60.86. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.